These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17548949)

  • 21. [A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin for chronic hepatitis C].
    Watanabe T; Inoue M; Harada K; Homma N; Uchida M; Ogata N; Funada R; Hasegawa K; Soga K; Shibasaki K
    Nihon Shokakibyo Gakkai Zasshi; 2006 Sep; 103(9):1061-6. PubMed ID: 16953104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus.
    Manjón-Haces JA; Vázquez-López F; Gómez-Díez S; Hidalgo-García A; Pérez-Alvarez R; Soler-Sánchez T; Pérez-Oliva N
    Acta Derm Venereol; 2001; 81(3):223. PubMed ID: 11558891
    [No Abstract]   [Full Text] [Related]  

  • 23. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
    Enríquez J; Gallego A; Torras X; Pérez-Olmeda T; Diago M; Soriano V; Luján MS; García-Samaniego J
    J Viral Hepat; 2000 Nov; 7(6):403-8. PubMed ID: 11115050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Granulomatous adenohypophysitis after interferon and ribavirin therapy.
    Tebben PJ; Atkinson JL; Scheithauer BW; Erickson D
    Endocr Pract; 2007; 13(2):169-75. PubMed ID: 17490932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
    de Lédinghen V; Trimoulet P; Winnock M; Bernard PH; Bourlière M; Portal I; Rémy AJ; Szostak N; Lévy S; Tran A; Abergel A; Chêne G; Fleury H; Couzigou P;
    J Hepatol; 2002 Jun; 36(6):819-26. PubMed ID: 12044534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
    Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
    de Lédinghen V; Trimoulet P; Winnock M; Foucher J; Bourlière M; Desmorat H; Canva V; Capron D; Lévy S; Mion F; Mannant PR; Chêne G; Fleury H; Couzigou P; Bernard PH;
    J Hepatol; 2002 May; 36(5):672-80. PubMed ID: 11983451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.
    Reiser M; Buggisch P; Grossmann J; Koop K; Wursthorn K; Schmiegel W
    Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1299-304. PubMed ID: 14624153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon.
    Mazzaro C; Zorat F; Comar C; Nascimben F; Bianchini D; Baracetti S; Donada C; Donadon V; Pozzato G
    J Rheumatol; 2003 Aug; 30(8):1775-81. PubMed ID: 12913934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: a case report.
    Tomasiewicz K; Modrzewska R; Semczuk G
    Adv Ther; 2006; 23(1):139-42. PubMed ID: 16644614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
    Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
    Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
    Carriero D; Fabrizi F; Uriel AJ; Park J; Martin P; Dieterich DT
    Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.
    Goto T; Ohshima S; Miura K; Shibuya T; Sato W; Dohmen T; Kamada K; Kanata R; Sakai T; Chiba M; Sugimoto Y; Minami S; Ohnishi H
    Intern Med; 2013; 52(18):2057-60. PubMed ID: 24042512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-alpha-induced destructive thyroiditis followed by Graves' disease in a patient with chronic hepatitis C: a case report.
    Kim BK; Choi YS; Park YH; Lee SU
    J Korean Med Sci; 2011 Dec; 26(12):1638-41. PubMed ID: 22148004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bell's palsy associated with IFN-alpha and ribavirin therapy for hepatitis C virus infection.
    Hoare M; Woodall T; Alexander GJ
    J Interferon Cytokine Res; 2005 Mar; 25(3):174-6. PubMed ID: 15767792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010.
    Barut S; Gunal O; Erkorkmaz U; Yildiz F
    Braz J Infect Dis; 2012; 16(5):448-51. PubMed ID: 22964290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.